Generic Alyftrek 50mg/20mg/4mg tablets
NHS hospitals in England used £36,798,692 of indicative cost of Generic Alyftrek 50mg/20mg/4mg tablets in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 0.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Generic Alyftrek 50mg/20mg/4mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Generic Alyftrek 50mg/20mg/4mg tablets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Royal Devon & Exeter Nhs Foundation Trst | £19,074,240 |
| King's College Hpl Nhs Foundation Trust | £2,126,520 |
| Leeds Teaching Hpls Nhs Trust | £1,917,090 |
| Alder Hey Childrens Nhs Foundation Trust | £1,836,540 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £1,594,890 |
| Guy's & St Thomas' Nhs Foundation Trust | £1,449,900 |
| Manchester University Nhs Ft | £1,304,910 |
| University Hpls North Midlands Nhs Trust | £1,208,250 |
| University Hpls Of Leicester Nhs Trust | £1,047,150 |
| Nottingham University Hospitals Trust | £998,820 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.